Key facts
- Snipr Biome’s last known valuation is $50.0M (Dec 2020).
- It has raised $135.8M; the latest was Later Stage VC ($40.8M) in Aug 2025.
- Notable investors include EQT Life Sciences, Wellington Partners, CARB-X, Cystic Fibrosis Foundation, Lundbeckfonden BioCapital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Snipr Biome
- ·The full record, as it builds
Funding rounds
No funding rounds for Snipr Biome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Snipr Biome
Developer of clustered regularly interspaced short palindromic repeats-based medicines designed to revolutionize the treatment of microbial diseases. The company's medicines utilize the adaptive immune system in a programmable way to kill target bacteria based on their specific genomes, enabling health professionals to access targeted microbiome engineering.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2011
- Employees
- 40
- Website
- sniprbiome.com/
- Ownership
- Privately Held (backing)
Snipr Biome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Snipr Biome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Snipr Biome in its N-PORT filings yet. We sweep new filings monthly.